Market Place
Sourcing Support
Pharmanovia Acquires Rights To Treatment For Parkinson’s Disease
07 Oct 2024 //
BUSINESSWIRE
Amneal Enters into European Licensing Agreement with Zambon Biotech for IPX203
27 Feb 2024 //
PRESS RELEASE
Safinamide mesylate by Zambon Co for Multiple System Atrophy Likelihood Approval
28 Aug 2023 //
PHARMACEUTICAL TECHNOLOGY
Aurobindo`s Generic Safinamide Mesylate Receives Approval in the U.S.
14 Jun 2023 //
FDA
RK Pharma Receives Generic Safinamide Mesylate Approval in the U.S
03 May 2023 //
FDA
Optimus` Generic Safinamide Mesylate Receives Approval in the U.S.
12 Jan 2023 //
FDA
Optimus` Generic Safinamide Receives Approval in the U.S.
12 Jan 2023 //
FDA
Newron provides H1 2022 results and updates on R&D and business activities
15 Sep 2022 //
BUSINESSWIRE
Newron & Zambon sign agreement for potentially pivotal study with safinamide
12 May 2021 //
PRESS RELEASE
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide
15 Mar 2021 //
BUSINESSWIRE
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide
15 Mar 2021 //
BUSINESSWIRE
Eisai launches Parkinson`s disease treatment Equfina in South Korea
02 Feb 2021 //
BIOSPECTRUMASIA
Eisai launches Parkinson`s disease treatment Equfina in South Korea
01 Feb 2021 //
BIOSPECTRUMASIA
Korea approves Equfina for Parkinson`s treatment
01 Jul 2020 //
BIOSPECTRUMASIA
Korea approves Equfina for Parkinson`s treatment
30 Jun 2020 //
BIOSPECTRUMASIA
Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
29 May 2020 //
BUSINESSWIRE
Supernus to Acquire CNS Portfolio from US WorldMeds
28 Apr 2020 //
GLOBENEWSWIRE
Valeo Pharma`s Onstryv® Receives +ve Recommendation for Public Reimbursement
06 Feb 2020 //
NEWSWIRE
Newron`s safinamide OK`d in Japan for Parkinson`s
20 Sep 2019 //
SEEKINGALPHA
Valeo Pharma Announces the Canadian Launch of Onstryv® (Safinamide Tablets)
11 Jul 2019 //
PRESS RELEASE
Zambon and Valeo Pharma launch PD drug Onstryv in Canada
11 Jul 2019 //
THE PHARMALETTER
Newron Receives First Tranche from Financing Agreement with EIB
28 Jun 2019 //
BIOSPACE
Valeo Pharma and Zambon announce the approval of Onstryv® (safinamide)
15 Jan 2019 //
PRESS RELEASE
Newron Pharmaceuticals S.p.A. Announces Change in the Board of Directors
18 Feb 2018 //
BUSINESSWIRE
Eisai: Primary Endpoint Met in Phase II / III Clinical Study Safinamide in Japan
01 Feb 2018 //
FINANCE
After disappointing 2016, new drug approvals roared back to life in 2017
02 Jan 2018 //
FIERCE BIOTECH
Zambon and Seqirus will collaborate to sell new Parkinson`s treatment
01 Nov 2017 //
PHARMALETTER
Xadago® (Safinamide) Now Available In The U.S. For Parkinson’S Disease Patients
31 Jul 2017 //
PRESS RELEASE
Valeo Pharma & Zambon Form Partnership for Parkinson’s Disease Treatment Xadago
11 Apr 2017 //
BUSINESSWIRE
Newron Hopes to Partner would-be Schizophrenia Blockbuster this Year
27 Jan 2017 //
FIERCE BIOTECH
Newron back on track for Xadago approval in US
09 Sep 2016 //
PMLIVE
Newron faces further FDA delay for Parkinson`s drug as regulator demand evidence
30 Mar 2016 //
FIERCE BIOTECH
Newron Pharmaceuticals` Xadago approved in EU to treat Parkinson’s disease
06 Nov 2015 //
EMA
FDA puts off its decision on Newron`s Parkinson`s drug
01 Oct 2015 //
FIERCE BIOTECH
